For research use only. Not for therapeutic Use.
Pertuzumab (Cat.No:I018812) is a monoclonal antibody used in the treatment of HER2-positive breast cancer. It targets the HER2 receptor and prevents its activation, thereby inhibiting cancer cell growth. Pertuzumab is often combined with other anti-HER2 therapies and has demonstrated efficacy in both early and metastatic breast cancer settings.
Catalog Number | I018812 |
CAS Number | 380610-27-5 |
Purity | ≥95% |
Target | Protein Tyrosine Kinase/RTK |
Reference | [1]. Nahta R, et al. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survivalof breast cancer cells. Cancer Res. 2004 Apr 1;64(7):2343-6.<br>[2]. Scheuer W, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009 Dec 15;69(24):9330-6. |